The Effect of Statins in Colorectal Cancer Is Mediated Through the Bone Morphogenetic Protein Pathway

Gastroenterology

Volumn 133, Issue 4, 2007, Pages 1272-1281

  Kodach, Liudmila L ^a   Bleuming, Sylvia A ^a   Peppelenbosch, Maikel P ^b   Hommes, Daniel W ^c   van den Brink, Gijs R ^a,c   Hardwick, James C H ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INHIBITOR OF DIFFERENTIATION 2; LUCIFERASE; MEVALONIC ACID; MEVINOLIN; NOGGIN; PRAVASTATIN; SIMVASTATIN; SMAD4 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ASSAY; FEMALE; GENE CONSTRUCT; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; TUMOR GROWTH; XENOGRAFT;

EID: 34548478602     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.08.021     Document Type: Article

References (40)

1. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., Low M., Greenson J.K., and Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
2. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 5 (2005) 930-942
3. Katz M.S. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2 (2005) 82-89
4. Jacobs E.J., Rodriguez C., Brady K.A., Connell C.J., Thun M.J., and Calle E.E. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98 (2006) 69-72
5. Downs J.R. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study 279 (1998) 1615-1622
6. Furberg C.D., Adams Jr. H.P., Applegate W.B., Byington R.P., Espeland M.A., Hartwell T., Hunninghake D.B., Lefkowitz D.S., Probstfield J., Riley W.A., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90 (1994) 1679-1687
7. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., and Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 77 (1980) 3957-3961
8. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65 (1996) 241-269
9. Agarwal B., Rao C.V., Bhendwal S., Ramey W.R., Shirin H., Reddy B.S., and Holt P.R. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117 (1999) 838-847
10. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., and Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5 (1999) 2223-2229
11. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
12. Prendergast G.C., Khosravi-Far R., Solski P.A., Kurzawa H., Lebowitz P.F., and Der C.J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10 (1995) 2289-2296
13. Wong W.W., Dimitroulakos J., Minden M.D., and Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16 (2002) 508-519
14. Agarwal B., Halmos B., Feoktistov A.S., Protiva P., Ramey W.G., Chen M., Pothoulakis C., Lamont J.T., and Holt P.R. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 23 (2002) 521-528
15. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., and Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946-1949
16. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M., Velculescu V.E., Traverso G., and Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28 (2001) 184-187
17. Howe J.R., Mitros F.A., and Summers R.W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 5 (1998) 751-756
18. Brosens L.A., van Hattem A., Hylind L.M., Iacobuzio-Donahue C., Romans K.E., Axilbund J., Cruz-Correa M., Tersmette A.C., Offerhaus G.J., and Giardiello F.M. Risk of colorectal cancer in juvenile polyposis. Gut 56 (2007) 965-967
19. Hardwick J.C., Van Den Brink G.R., Bleuming S.A., Ballester I., Van Den Brande J.M., Keller J.J., Offerhaus G.J., Van Deventer S.J., and Peppelenbosch M.P. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126 (2004) 111-121
20. Mantel-Teeuwisse A.K., Klungel O.H., Schalekamp T., Verschuren W.M., Porsius A.J., and de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol 60 (2005) 83-89
21. Woodford-Richens K.L., Rowan A.J., Gorman P., Halford S., Bicknell D.C., Wasan H.S., Roylance R.R., Bodmer W.F., and Tomlinson I.P. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci U S A 98 (2001) 9719-9723
22. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., and Warwick M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87 (2001) 28B-32B
23. Zhou S., Buckhaults P., Zawel L., Bunz F., Riggins G., Le Dai J., Kern S.E., Kinzler K.W., and Vogelstein B. Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells 10.1073/pnas.95.5.2412. PNAS 95 (1998) 2412-2416
24. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., Affolter M., Vale W.W., Belmonte J.C., and Choe S. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420 (2002) 636-642
25. Beck S.E., Jung B.H., Fiorino A., Gomez J., Rosario E.D., Cabrera B.L., Huang S.C., Chow J.Y., and Carethers J.M. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291 (2006) G135-G145
26. Pan H.Y., DeVault A.R., Wang-Iverson D., Ivashkiv E., Swanson B.N., and Sugerman A.A. Comparative pharmacokinetics and pharmacodynamics of Pravastatin and lovastatin. J Clin Pharmacol 30 (1990) 1128-1135
27. Coogan P.F., Smith J., and Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 99 (2007) 32-40
28. Reddy B.S., Wang C.X., Kong A.N., et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66 (2006) 4542-4546
29. Narisawa T., Fukaura Y., Tanida N., Hasebe M., Ito M., and Aizawa R. Chemopreventive efficacy of low dose of Pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 180 (1996) 131-138
30. Narisawa T., Morotomi M., Fukaura Y., Hasebe M., Ito M., and Aizawa R. Chemoprevention by Pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87 (1996) 798-804
31. Swamy M.V., Patlolla J.M.R., Steele V.E., Kopelovich L., Reddy B.S., and Rao C.V. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCM in mice. 10.1158/0008-5472. CAN-05-4619. Cancer Res 66 (2006) 7370-7377
32. Kim K.P., Whitehead C., Piazza G., and Wargovich M.J. Combinatorial chemoprevention: efficacy of lovastatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 24 (2004) 1805-1811
33. Taras D., Blanc J.F., Rullier A., Dugot-Senant N., Laurendeau I., Vidaud M., and Rosenbaum J. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 46 (2007) 69-76
34. Holstein S.A., Knapp H.R., Clamon G.H., Murry D.J., and Hohl R.J. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57 (2006) 155-164
35. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J.P., Soria J., and Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22 (2002) 623-629
36. Sebti S.M., Tkalcevic G.T., and Jani J.P. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 3 (1991) 141-147
37. Khan S.G., Saxena R., Bickers D.R., Mukhtar H., and Agarwal R. Inhibition of ras p21 membrane localization and modulation of protein kinase C isozyme expression during regression of chemical carcinogen-induced murine skin tumors by lovastatin. Mol Carcinog 12 (1995) 205-212
38. Xia Z., Tan M.M., Wong W.W., Dimitroulakos J., Minden M.D., and Penn L.Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15 (2001) 1398-1407
39. Muller C., Bockhorn A.G., Klusmeier S., Kiehl M., Roeder C., Kalthoff H., and Koch O.M. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 12 (1998) 717-723
40. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., Willson J.K., Markowitz S., Hamilton S.R., Kern S.E., Kinzler K.W., and Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13 (1996) 343-346